相关实验视频

Updated: Jan 17, 2026

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS

Published on: December 27, 2013

双相异化物输送系统:PLGA纳米颗粒嵌入热敏PLGA-PEG-PLGA水凝中,用于持续的血糖控制

Shu Pan¹, Nan Dong¹, Haoyang Yuan¹

¹Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning, PR China.

Expert opinion on drug delivery

|September 22, 2025

概括

在热敏水凝中使用exenatide纳米颗粒的新双相传递系统为2型糖尿病治疗提供了持续释放. 这种可注射配方可以改善药物输送和患者遵守糖尿病和肥胖症的管理.

科学领域:

生物医学工程生物医学工程
药物输送系统药物输送系统
药理学药理学是指药理学的学科.

背景情况:

葡萄糖类-1 (GLP-1) 受体激动剂对2型糖尿病 (T2DM) 和肥胖有效.
限制包括低口服生物利用率和频繁的注射,阻碍患者遵守.
为了应对这些挑战,开发了一种新的双相传递系统.

研究的目的:

开发和评估一个双相传递系统 (Ex-NPs-gel) 持续释放的exenatide.
通过加强药物输送,改善T2DM和肥胖症的治疗结果.

主要方法:

使用双重乳液溶剂蒸发制备了装载着exenatide的纳米粒子 (Ex-NPs).
前NP被封装成一个热敏水凝 (PLGA-PEG-PLGA) 的poly (乳糖-co-甘油酸) -poly (乙烯基甘油) -poly (乳糖-co-甘油酸).
评估了物理化学性质和体外/体内性能.

主要成果:

在Ex-NPs凝系统中,在31天内持续释放exenatide,初始爆发释放最小 (在24小时内<9%).
在T2DM大鼠模型中,单次给药稳定了超过15天的禁食血糖.
该配方在动物模型中恢复了肝脏和胰腺功能.

结论:

双相传递系统克服了传统PLGA载体和单相凝的局限性.
该系统调节释放动力学,以有效地提供长效的多.
该Ex-NPs-凝配方为T2DM和肥胖管理提供了一个生物相容和临床可转换的解决方案.

关键词:

甲酸是一种甲酸.纳米颗粒是一种纳米粒子.持续释放持续释放持续释放热敏水凝是一种热敏水凝.2 型糖尿病 2 型糖尿病

更多相关视频

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release

Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release

Published on: February 13, 2016

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...